Cargando…
A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy
Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809115/ https://www.ncbi.nlm.nih.gov/pubmed/35039873 http://dx.doi.org/10.3892/mmr.2022.12604 |
_version_ | 1784643951507013632 |
---|---|
author | Nonaka, Wakako Takata, Tadayuki Iwama, Hisakazu Komatsubara, Satoshi Kobara, Hideki Kamada, Masaki Deguchi, Kazushi Touge, Tetsuo Miyamoto, Osamu Nakamura, Takehiro Itano, Toshifumi Masaki, Tsutomu |
author_facet | Nonaka, Wakako Takata, Tadayuki Iwama, Hisakazu Komatsubara, Satoshi Kobara, Hideki Kamada, Masaki Deguchi, Kazushi Touge, Tetsuo Miyamoto, Osamu Nakamura, Takehiro Itano, Toshifumi Masaki, Tsutomu |
author_sort | Nonaka, Wakako |
collection | PubMed |
description | Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because there are no established biomarkers, and diagnosis is currently based on clinical and imaging findings. Furthermore, the etiology and pathogenesis of PSP remain unknown. Dysregulation of microRNAs (miRNAs/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of patients with PSP are rarely reported. The present study aimed to examine cerebrospinal fluid miRNAs, which are considered to be more sensitive indicators of changes in the brain, to elucidate the pathophysiology of PSP and to establish specific biomarkers for diagnosis. The present study used a microarray chip containing 2,632 miRNAs to examine cerebrospinal fluid miRNA expression levels in 11 patients with PSP aged 68–82 years. A total of 8 age- and sex-matched controls were also included. A total of 38 miRNAs were significantly upregulated and one miRNA was significantly downregulated in the cerebrospinal fluid of patients with PSP. The patients were divided into two groups based on disease stage (early onset and advanced), and changes in miRNA expression were examined. The miRNAs that were most significantly upregulated or downregulated in the early onset group were miR-204-3p, miR-873-3p and miR-6840-5p. The target genes of these miRNAs were associated with molecules related to the ubiquitin-proteasome system and autophagy pathway. Furthermore, these miRNAs were found to target genes that have been reported to have epigenetic changes following an epigenome-wide association study of brain tissues of patients with PSP. This suggested that these miRNAs and genes may have some involvement in the pathogenesis of PSP. However, the sample size of the present study was small; therefore, a greater number of patients with PSP should be examined in future studies. |
format | Online Article Text |
id | pubmed-8809115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-88091152022-02-03 A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy Nonaka, Wakako Takata, Tadayuki Iwama, Hisakazu Komatsubara, Satoshi Kobara, Hideki Kamada, Masaki Deguchi, Kazushi Touge, Tetsuo Miyamoto, Osamu Nakamura, Takehiro Itano, Toshifumi Masaki, Tsutomu Mol Med Rep Articles Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because there are no established biomarkers, and diagnosis is currently based on clinical and imaging findings. Furthermore, the etiology and pathogenesis of PSP remain unknown. Dysregulation of microRNAs (miRNAs/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of patients with PSP are rarely reported. The present study aimed to examine cerebrospinal fluid miRNAs, which are considered to be more sensitive indicators of changes in the brain, to elucidate the pathophysiology of PSP and to establish specific biomarkers for diagnosis. The present study used a microarray chip containing 2,632 miRNAs to examine cerebrospinal fluid miRNA expression levels in 11 patients with PSP aged 68–82 years. A total of 8 age- and sex-matched controls were also included. A total of 38 miRNAs were significantly upregulated and one miRNA was significantly downregulated in the cerebrospinal fluid of patients with PSP. The patients were divided into two groups based on disease stage (early onset and advanced), and changes in miRNA expression were examined. The miRNAs that were most significantly upregulated or downregulated in the early onset group were miR-204-3p, miR-873-3p and miR-6840-5p. The target genes of these miRNAs were associated with molecules related to the ubiquitin-proteasome system and autophagy pathway. Furthermore, these miRNAs were found to target genes that have been reported to have epigenetic changes following an epigenome-wide association study of brain tissues of patients with PSP. This suggested that these miRNAs and genes may have some involvement in the pathogenesis of PSP. However, the sample size of the present study was small; therefore, a greater number of patients with PSP should be examined in future studies. D.A. Spandidos 2022-03 2022-01-14 /pmc/articles/PMC8809115/ /pubmed/35039873 http://dx.doi.org/10.3892/mmr.2022.12604 Text en Copyright: © Nonaka et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Nonaka, Wakako Takata, Tadayuki Iwama, Hisakazu Komatsubara, Satoshi Kobara, Hideki Kamada, Masaki Deguchi, Kazushi Touge, Tetsuo Miyamoto, Osamu Nakamura, Takehiro Itano, Toshifumi Masaki, Tsutomu A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title | A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title_full | A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title_fullStr | A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title_full_unstemmed | A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title_short | A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy |
title_sort | cerebrospinal fluid microrna analysis: progressive supranuclear palsy |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809115/ https://www.ncbi.nlm.nih.gov/pubmed/35039873 http://dx.doi.org/10.3892/mmr.2022.12604 |
work_keys_str_mv | AT nonakawakako acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT takatatadayuki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT iwamahisakazu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT komatsubarasatoshi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT kobarahideki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT kamadamasaki acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT deguchikazushi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT tougetetsuo acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT miyamotoosamu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT nakamuratakehiro acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT itanotoshifumi acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT masakitsutomu acerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT nonakawakako cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT takatatadayuki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT iwamahisakazu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT komatsubarasatoshi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT kobarahideki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT kamadamasaki cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT deguchikazushi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT tougetetsuo cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT miyamotoosamu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT nakamuratakehiro cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT itanotoshifumi cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy AT masakitsutomu cerebrospinalfluidmicrornaanalysisprogressivesupranuclearpalsy |